ערך בספרים למניה: Zevra Therapeutics (ZVRA)

Zevra Therapeutics (ZVRA) relies on its own proprietary system for developing therapies for rare CNS pathologies, which guarantees a lack of competition and pricing power. Stable demand for the treatment of genetic disorders ensures the company's long-term revenue sustainability. The current figure stands at 3.69, and the launch of sales for approved drugs is creating a liquidity inflow. The asset value tracked on this chart confirms a decreasing dependence on cash reserves.

Zevra Therapeutics (ZVRA) minimizes business vulnerability to shocks by capitalizing on exclusive rights to the drug Myplysa and developing a patient tracking IT system, both of which create a significant margin of safety. By analyzing the fair book value per share, an investor sees the remaining equity after deducting all liabilities, allowing for an assessment of the asset's real value independent of market speculation.